November Committee. Page 1 of 16
|
|
- Shana Nash
- 7 years ago
- Views:
Transcription
1 PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF PROCEDURE: REASON FOR THE PROCEDURE: WHAT THE PROCEDURE WILL ACHIEVE: WHO NEEDS TO KNOW ABOUT IT: DATE APPROVED: VERSION NUMBER: APPROVING COMMITTEE: Medicines Procedure: Lithium Therapy: Prescribing and Monitoring The Patient Safety Alert NPSA 2009/PSA005: Safer lithium therapy 1. Reduce risk 2. Facilitate confident prescribing, monitoring, administration and dispensing of lithium 3. Improve awareness All staff involved in the prescribing, dispensing or administering of lithium November Executive Board DATE OF IMPLEMENTATION: November 2014 DATE OF FORMAL REVIEW: November 2017 AUTHOR/REVIEWER: DIRECTORATE RESPONSIBLE: DISTRIBUTION: Medicines Management Committee All staff involved in the prescribing, dispensing or administering of lithium Page 1 of 16
2 POLICY, PROCEDURE AND GUIDELINE DEVELOPMENT PROCEDURE VERSION CONTROL SHEET Version Date Author Status Comment 0.1 March 2011 Fiona Lockwood 0.2 September 11 Simon Whitfield 1.1 October 14 Fiona Lockwood draft Draft ready for Oct 11 PAG Draft ready for Nov 14 PAG New procedure sent out for consultation Reviewed but no changes necessary Page 2 of 16
3 Summary of Changes since Version 1.0 (Include version control number here) Page /Paragraph/ Appendix Number (select the appropriate action) Original / New / Amendment / Deleted Statement (select the appropriate action) No changes since consultation Page 3 of 16
4 PROCEDURE FOR THE PRESCRIBING AND MONITORING OF LITHIUM THERAPY 1.0 INTRODUCTION In December 2009 the NPSA issued a Patient Safety Alert on safer lithium therapy. The alert was in response to reports of harm caused to individuals, including fatalities, involving lithium therapy. This procedure sets out guidelines to ensure that this Patient Safety Alert is complied with when lithium is prescribed, monitored, administered and dispensed. 2.0 RELATED POLICY The Medicines Policy. 3.0 ON ADMISSION 3.1 INITIATION (ALSO APPLIES IN COMMUNITY SETTING see the Trust Lithium Amber* information sheet for prescribing in the community) Ensure the following baseline data has been established before commencement of treatment: ECG if there are risk factors for, or existing cardiovascular disease Weight and height Urea and Electrolytes Serum creatinine Thyroid Function Tests; specifically TSH. If TSH abnormal, test T3 and T4 Full blood count if clinically indicated Plasma level of lithium must be taken 12 hours post dose; checked 1 week after initiation and 1 week after every dose change and until the levels are stable. (See Appendix 1) The starting dose is normally 400mg (200mg in the elderly). Page 4 of 16
5 3.1.4 Doses should be adjusted to achieve a plasma lithium concentration between 0.4 and 1.0mmol/L in people being prescribed it for the first time. The lower end of the range is usually the target for maintenance therapy and treatment of elderly individuals If an individual has just been initiated on lithium, the pharmacist should check that the baseline monitoring tests have been carried out (see Appendix 1). If not, the prescriber should be informed of the need for monitoring. 3.2 ADMITTED ON LITHIUM The admitting doctor must: Read the individual s notes and previous prescription, check individual s documentation (either a record book and alert card or a monitoring booklet) and identify any special instructions. Review the results of all relevant investigations (including blood test results) and identify the indication for the lithium therapy. 2 At the earliest opportunity contact the individual s GP for advice, if the individual is admitted without an up-to-date documentation. 2 Ensure that the individual fully understands their lithium treatment and monitoring requirements and if not, provide a clear explanation. Ensure the correct brand of lithium is prescribed as different preparations may vary in bioavailability; care should be taken when changing brands or formulations and should be regarded as initiation of new treatment Pharmacy team responsibilities: The medicines management technician should alert the ward pharmacist to any individual prescribed lithium and any subsequent additional items prescribed. The medicines management technician or ward pharmacist should undertake a full drug history on admission and record the brand of lithium on the drug chart in the additional information box and in the individual s notes. N.B. this information may be obtained from the individual s lithium record book. If individuals are admitted on lithium they should be asked to produce their lithium record book by a pharmacist or technician. This is to ensure that there is no ambiguity regarding dosage and formulation and that monitoring has occurred. A supply can be made from the local Pharmacy if required. Page 5 of 16
6 Any patient s own lithium brought into hospital should be checked in accordance with the Patient s Own Drugs Procedure. The pharmacist should review the in-patient medicine chart before any supply is made and ensure that the prescription is complete and accurate, the brand stated and that monitoring is in place. The ward pharmacist should check if the routine monitoring tests have been carried out (see Appendix 2). If these results are not accessible, pharmacists should inform medical staff to request the relevant tests. As a principle, therapy should not be withheld but the prescriber informed of the need for monitoring. The pharmacist should check for any drug interactions. If the individual is prescribed other potentially interacting medicines e.g. NSAIDs, diuretics or if an interacting medicine is discontinued, the prescriber should be contacted to ensure they are aware of the interaction and that arrangements have been made for additional tests to be carried out if necessary. 3.3 CONTINUING TREATMENT ON ADMISSION Where necessary, the care team must update the monitoring results in the individual s record book Nurses responsibilities: Nurses need to be aware of common side effects of lithium listed below and report to the ward doctor if they have concerns. Gastro-intestinal disturbances Fine tremor Renal impairment (particularly impaired urinary concentration and polyuria) Polydipsia Leucocytosis Weight gain Oedema (may respond to dose reduction) Nurses need to monitor the individual and report to the ward doctor if symptoms of lithium toxicity appear. (See Appendix 3) Nurses must also: Inform anyone who is involved in the individual s care, that the individual is taking lithium. Page 6 of 16
7 Advise the individual to avoid dietary changes which reduce or increase sodium intake. Advise the individual to avoid the use of over the counter analgesics such as ibuprofen Prescribers responsibilities: Record lithium levels on the drug chart with the date of the test and enter in the notes. Be aware of any significant interacting drugs and other risk factors for lithium toxicity. (See Appendix 3) Undertake more frequent blood tests and lithium levels if there are signs of clinical deterioration, abnormal results, and symptoms suggesting abnormal renal or thyroid function such as unexplained fatigue. 1 Repeat lithium levels if they initiate or discontinue any interacting drugs. (Check at 7 day intervals until two similar results are obtained at the same dose). 1 Repeat lithium levels if they increase or decrease lithium dose. (Check at 7 day intervals until two similar results are obtained at the same dose). Be aware that toxicity occurs when blood lithium concentration is greater than 1.5mmol/L. (Usual therapeutic range is between mmol/L for people being prescribed it for the first time.) For people who have relapsed previously while taking lithium or who have sub-threshold symptoms with functioning impairment while on lithium target level is normally between mmol/L 1 Monitor for symptoms of neurotoxicity, including paraesthesia, ataxia, tremor and cognitive impairment, which can occur at therapeutic levels. Consider stopping lithium for up to 7 days if individuals become acutely and severely ill with any metabolic or respiratory disturbance. 1 STOP lithium immediately, if any of the symptoms of toxicity occur. (See appendix 3). Plasma lithium levels should be urgently checked and the individual rehydrated with an increased sodium intake. Levels of 2mmol/L or more require urgent treatment as per guidance in the BNF and Maudsley Prescribing Guidelines. 3, 4 Page 7 of 16
8 Exclude pregnancy (and test if appropriate) in women of child bearing potential and advise these individuals to use suitable contraception. (If a individual becomes pregnant, refer for specialist advice) Pharmacy team responsibilities: Check that blood tests and lithium levels have been obtained at the appropriate times and where not, arrange for them to be taken as necessary. Check that the latest lithium level (and date) is written on the drug chart. If it is not, check the clinical notes and make the appropriate drug chart entry. Ask individuals who have been admitted on lithium if they have a lithium record book. Where possible, check that this is correctly completed. Review the drug chart before any supply is made and ensure that the prescription is complete, the brand stated and that monitoring is in place. Before endorsing the chart all prescriptions must be checked for drug interactions, which must be reported back to the prescriber as necessary. Ensure the importance of administering lithium in the evening (for tablets) is clear to the medical and nursing team. Pharmacists should not withhold lithium therapy. Where it is not possible to assess monitoring they should communicate to prescribers that lithium medication has been provided without blood test data being available and that this should be investigated as soon as possible ON DISCHARGE 4.1 Prescribers responsibilities: Ensure that the primary care team is sent information concerning the clinical indication of use, intended duration of therapy, current prescription (including product brand name), and recent laboratory test results. Ensure that the record book or monitoring booklet is FULLY and appropriately completed (with individual s details, service providers details and current lithium therapy to track lithium blood levels and relevant clinical tests) and that it is returned to individual/carer, with the next appointment date recorded. 2 Page 8 of 16
9 Use the Trust Lithium Amber* information sheet to liaise with the individual s GP for prescribing and monitoring lithium and also checking adverse effects. Ensure individuals receive regular measurement of serum-lithium concentration (every 3 months on stabilised regimen), and also renal function and thyroid function tests every 6 months on stabilised regimens, or more often if there is evidence of impaired renal function Nursing Team responsibilities: Ensure the following are discussed with the individual: The dose they should be taking on discharge and the frequency. The date of their next appointment for a blood test. The importance of their individual-held records, (record book, alert card and patient information booklet). The need to take lithium at the same time each day (usually in evening) 4.3 Pharmacy Team responsibilities: For newly initiated individuals, pharmacists should ensure that the individual has received a lithium record book and that they have been advised to produce this record book each time they have contact with a healthcare professional Pharmacists should ensure that the individual has been counselled on the frequency of administration, strength of tablets/liquid, dietary advice, signs and symptoms of toxicity etc. as well as common interactions e.g. NSAIDs (see Appendices 3 & 4) The record book should be updated on discharge if any changes have occurred to the lithium dose whilst an in-patient; this should be checked by a pharmacist. The book should state the dose, brand and a record of blood tests. This should be completed by medical staff but may be completed by a pharmacist. Ask the individual if they have any questions about their lithium or if they have noticed any side effects. If side effects are experienced, the pharmacist should discuss them with the prescriber as they could be signs of toxicity or intolerance. Ensure the individual is aware of the potential of lithium to interact with other medications. (See Appendix 4) Page 9 of 16
10 Remind the individual to report any unusual signs and symptoms to their G.P: e.g. sore throat, bruising, mouth ulcers, nausea, vomiting, dark urine and shortness of breath. Give the individual a lithium information booklet if they have not already received one along with an alert card. Ensure they are adequately counselled, particularly if their ability to read the booklet is in question. Ensure the monitoring record book is returned to individual with all sections filled appropriately. This should include the individual s details, service provider s details, current lithium therapy and the date for next appointment for blood monitoring. 2 Advise the individual to monitor and report any signs or symptoms suggestive of hypothyroidism such as lethargy and feeling cold. Advise the individual to maintain a constant fluid and salt intake and avoid large dietary changes. Page 10 of 16
11 REFERENCES 1. National Institute for Clinical Excellence (NICE). Bipolar Disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Clinical Guideline 38, National Patient Safety Agency (NPSA) Alerts Summary Lithium Dec BNF No 60 September Maudsley Prescribing Guidelines 9 th edition, 2007, pg Dorset Healthcare NHS Foundation Trust. Ref No CP , lithium prescribing & Monitoring Guidelines 6. Stockley s Drug Interaction 7 th edition Chapter 29, Pg Guidelines for the Prescribing and Monitoring of Lithium Therapy: Sussex Partnership NHS Foundation Trust Page 11 of 16
12 Appendix 1 BASELINE MONITORING Parameter Notes Initial assessment of suitability for lithium treatment Renal Function Thyroid Function Full Blood Count ECG Specifically urea, electrolytes and serum creatinine to calculate Egfr Specifically TSH; if TSH abnormal, test T3 and T4 levels Only if clinically indicated Before initiation if there are risk factors for or existing cardiovascular disease Weight and Height Serum Levels of Lithium Level must be taken 12 hours post dose, checked 1 week after starting and 1 week after every dose change, and until the levels are stable Page 12 of 16
13 Appendix 2 ROUTINE MONITORING Parameter Frequency Notes Renal Function Thyroid Function Full Blood Count Weight and Height Serum Levels of Lithium Every 6 months; more often if there is evidence of deterioration or the individual starts taking drugs such as ACE inhibitors, diuretics or NSAIDs Every 6 months; more often if evidence of deterioration Only if clinically indicated If individual continues to gain weight Every 3 months or if dose change or some other indication or evidence of deterioration, then 1 week after every dose change, and until the levels are stable, then every 3 months Specifically urea, electrolytes and serum creatinine to calculate egfr Specifically TSH; if TSH abnormal, test T3 and T4 levels Page 13 of 16
14 Appendix 3: Lithium Toxicity. Symptoms of lithium toxicity 1) Severe nausea 2) Anorexia 3) Vomiting or diarrhea 4) Muscle weakness 5) Coarse tremor 6) Ataxia 7) Myoclonus (unexplained involuntary jerks) 8) Blurred vision 9) Drowsiness or increased disorientation 10) Confusion 11) Arrhythmias 12) Renal failure 13) Circulatory failure 14) Hypothyroidism 15) Hypokalaemia 16) Raised anti-diuretic hormone concentration 17) Coma 18) Occasionally death When lithium blood levels are above 2mmol/l and severe symptoms are present, osmotic diuresis or forced alkaline diuresis should be initiated. (Note: concurrent use of diuretics, particularly thiazides, should be avoided). 3 Page 14 of 16
15 Appendix 4: Information for Clinicians on Managing Lithium Drug Interactions DRUG ACE inhibitors e.g. enalapril, Angiotensin-II antagonists e.g. losartan Analgesics (NSAIDs) e.g. diclofenac, ibuprofen, aspirin Anti-arrhythmics e.g. amiodarone Antidepressants eg. SSRIs, Tricyclics, venlafaxine Diuretics (thaizides, potassiumsparing and loop diuretics) Methyldopa Antiepileptics e.g. carbamazepine, phenytoin, topiramate Antacids e.g. Sodium bicarbonate Metronidazole Calcium channel blockers Theophylline Parasympathomimetics Acetazolamide Antipsychotics Muscle Relaxants Lithium Interaction Alert 3, 6 INTERACTION Excretion reduced, Increased plasma concentration. May cause toxicity. Monitor closely for signs of lithium toxicity, and consider taking lithium levels. Be alert for the need to reduce the lithium dose (possibly by one-third to half). Excretion of lithium reduced. Increased risk of toxicity. Avoid concomitant use. Paracetamol based painkillers are safer to use with lithium. Risk of ventricular arrhythmias. Avoid concomitant use. Increased serotogenic effects seen and an increased risk of CNS effects as well as risk of lithium toxicity reported. All can increase lithium toxicity without affecting lithium levels. Excretion reduced. Increased plasma concentration and risk of toxicity. Loop diuretics are safer than thaizides. Neurotoxicity may occur without increasing plasma concentration of lithium. Avoid concurrent use whenever possible. Neurotoxicity may occur without increased lithium plasma concentrations. Moderate interaction Excretion increased. Reduced plasma concentration. Increased risk of lithium toxicity Neurotoxicity may occur with diltiazem or verapamil without increasing the plasma concentration of lithium. Increased excretion of lithium. Reduced plasma lithium concentration. Depressive and manic relapse may occur if the dosage of lithium is not raised when theophylline is given. Lithium levels should be monitored if theophylline (or aminophylline) is stopped, started or altered. Lithium antagonises the effects of neostigmine and pyridostigmine. Excretion of lithium is reduced. Increased risk of extrapyramidal side effects and possible neurotoxicity. Sertindole increases risk of ventricular arrhythmias - avoid concomitant use. Lithium enhances the effect of muscle relaxants. Hyperkinesis caused by lithium is aggravated by baclofen. Page 15 of 16
16 DRUG DISEASE INTERACTION (Other risk factors) If renal impairment exists, avoid use of lithium (if possible) or reduce dose and closely monitor serum-lithium concentration. 3 Cardiac disease and conditions with sodium imbalance such as Addison s disease will require dose reduction or discontinuation. Similarly, in severe diarrhoea and/or vomiting and in concurrent infection, (especially if sweating profusely). 3 Psoriasis: risk of exacerbation. 3 Page 16 of 16
SHARED CARE GUIDELINE FOR LITHIUM. 1. Aim/Purpose of this Guideline. 2. The Guidance
SHARED CARE GUIDELINE FOR LITHIUM 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of lithium.
More informationLithium initiated by Secondary Care (Mental Health) Prescribe by Brand Name (usually Priadel)
Nottinghamshire Health Community Algorithm for Prescribing and Monitoring Lithium within Primary and Secondary Care (Mental Health) Traffic Light Classification - Amber 2 Information sheet for Primary
More informationLithium Therapy. Important information for patients COLLEGE CENTRE FOR QUALITY IMPROVEMENT
Lithium Therapy Important information for patients COLLEGE CENTRE FOR QUALITY IMPROVEMENT National Patient Safety Agency National Patient Safety Agency Your information Your name: Address: Postcode: Home
More information**Form 1: - Consultant Copy** Telephone Number: Fax Number: Email: Author: Dr Bernard Udeze Pharmacist: Claire Ault Date of issue July 2011
Effective Shared Care Agreement for the treatment of Dementia in Alzheimer s Disease Donepezil tablets / orodispersible tablets (Aricept / Aricept Evess ) These forms (1 and 2) are to be completed by both
More information3. Prophylactic treatment of recurrent affective disorders.
PRIADEL Lithium carbonate Presentation Controlled release lithium carbonate tablets. White circular, bi-convex tablets engraved PRIADEL on one side, scored on the other side. Each tablet contains 400 mg
More informationGMMMG Interface Prescribing Subgroup. Shared Care Template
GMMMG Interface Prescribing Subgroup Shared Care Template Shared Care Guideline for Selective Serotonin Reuptake Inhibitors (SSRIs) for the treatment of Obsessive Compulsive Disorder (OCD) and Body Dysmorphic
More informationDonepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa )
Donepezil (Aricept ), Galantamine (Reminyl XL ), Rivastigmine (Exelon ) and Memantine (Ebixa ) ESCA: For the treatment of Alzheimer s disease. SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR
More informationDabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationNaltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance
Naltrexone Shared Care Guideline for the treatment of alcohol dependence and opioid dependance Introduction Indication/Licensing information: Naltrexone is licensed for use as an additional therapy, within
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationRivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF
Leeds Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF Amber Drug Level 3 (amber drug with monitoring requirements) We have started your
More informationAcetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD)
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Acetylcholinesterase Inhibitors and Memantine Clinical Indication: Treatment of Dementia in Alzheimer s Disease (AD) Version: 3 Date Approved: June 2011 Review
More informationRivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)
Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE) Amber Drug Level 2 Leeds We have started your patient on rivaroxaban for the treatment of provoked VTE (deep
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationLEFLUNOMIDE (Adults)
Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) SHARED CARE AGREEMENT FRAMEWORK ACAMPROSATE CALCIUM (Campral EC) for alcohol abstinence ESCA: Adjunct in the treatment of chronic alcohol dependence (under
More informationSECTION 6 THERAPEUTIC DRUG MONITORING
SECTION 6 THERAPEUTIC DRUG MONITORING Kieran Hand Consultant Pharmacist Anti-infectives The objectives of this section are: To test your ability to monitor serum levels for drugs with a narrow therapeutic
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
Diabetic ketoacidosis in children and young people bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They
More informationEssential Shared Care Agreement Drugs for Dementia
Ref No. E040 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1.
More informationSouthern Derbyshire Shared Care Pathology Guidelines. Hyperkalaemia
Southern Derbyshire Shared Care Pathology Guidelines Hyperkalaemia Purpose of Guideline Dealing with adult patients with Hyperkalaemia in the community Definition Serum potassium normal range is 3.5 5.3
More informationPPP 1. Continuation of a medication to ensure continuity of care
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationNorth of Tyne Area Prescribing Committee
North of Tyne Area Prescribing Committee ANTIPSYCHOTICS IN PSYCHOSIS, BIPOLAR DISORDER AND AUGMENTATION THERAPY IN TREATMENT RESISTANT DEPRESSION Information for Primary Care Updated November 2013 This
More informationNurse Initiated Medications Procedure
1. Purpose This Procedure is performed as a means of ensuring the safe administration of therapeutic medication to patients in accordance with all legislative and regulatory requirements. 2. Application
More informationInformation for Prescribing Anti-dementia Drugs. November 2012
Information for Prescribing Anti-dementia Drugs The aim of this document is to provide information about the prescribing of anti-dementia medication for adult patients with dementia following an assessment
More informationGuidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care
Hull & East Riding Prescribing Committee Guidelines for the Prescribing, Supply and Administration of Methadone and Buprenorphine on Transfer of Care 1. BACKGROUND Patients who are physically dependent
More informationMEDICATION GUIDE. TRINTELLIX [trin -tel-ix] (vortioxetine) Tablets
MEDICATION GUIDE TRINTELLIX [trin -tel-ix] (vortioxetine) Tablets Read this Medication Guide before you start taking TRINTELLIX and each time you get a refill. There may be new information. This information
More informationLithium. Generic name = lithium carbonate (tablets and capsules), or lithium citrate (liquid)
Lithium Brand and Generic Names Eskalith - Capsules: 300 mg Eskalith CR slow release - Tablets: 450 mg Lithobid slow release - Tablets: 300 mg Generic name = lithium carbonate (tablets and capsules), or
More informationMedicines reconciliation on admission and discharge from hospital policy April 2013. WHSCT medicines reconciliation policy 1
Medicines reconciliation on admission and discharge from hospital policy April 2013 WHSCT medicines reconciliation policy 1 Policy Title Policy Reference Number Medicines reconciliation on admission and
More informationTrileptal (Oxcarbazepine)
Brand and Generic Names: Trileptal Tablets: 150mg, 300mg, 600mg Liquid Suspension: 300mg/5mL Generic name: oxcarbazepine What is Trileptal and what does it treat? Trileptal (Oxcarbazepine) Oxcarbazepine
More informationPOAC CLINICAL GUIDELINE
POAC CLINICAL GUIDELINE Acute Pylonephritis DIAGNOSIS COMPLICATED PYELONEPHRITIS EXCLUSION CRITERIA: Male Known or suspected renal impairment (egfr < 60) Abnormality of renal tract Known or suspected renal
More informationPatient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust.
Patient Group Direction Hospital: Bristol Royal Infirmary Department: UHBristol Thrombosis Service University Hospitals Bristol NHS Foundation Trust. This Patient Group Direction (PGD) has been written
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationPaxil/Paxil-CR (paroxetine)
Generic name: Paroxetine Available strengths: 10 mg, 20 mg, 30 mg, 40 mg tablets; 10 mg/5 ml oral suspension; 12.5 mg, 25 mg, 37.5 mg controlled-release tablets (Paxil-CR) Available in generic: Yes, except
More informationpatient group direction
DICLOFENAC v01 1/8 DICLOFENAC PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More informationBest Practices Patient Monitoring Parameters for Mood Stabilizers*
Best Practices Patient Monitoring Parameters for Mood Stabilizers* All Mood Stabilizers Baseline 6 months Annually As Clinically General Physical Assessment (blood pressure, heart rate, height, weight,
More informationThere is a risk of renal impairment in dehydrated children and adolescents.
PACKAGE LEAFLET: INFORMATION FOR THE USER MELFEN 200mg FILM-COATED TABLETS MELFEN 400mg FILM-COATED TABLETS Ibuprofen Read all of this leaflet carefully before you start taking this medicine because it
More informationShared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia Version: 3.0 Ratified by: Medicines Committee Date ratified: 16 th November 2011 Name of originator/author: James
More informationPRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ANTICOAGULANT THERAPY
PRESCRIBING GUIDELINES FOR THE MANAGEMENT OF PATIENTS ON ANTICOAGULANT THERAPY Prepared by: NPSA Anticoagulation Steering Group Approved by: Wirral Drug & Therapeutics Committee 14 th May 2008 Review:
More informationA Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood.
Bipolar disorder Bipolar (manic-depressive illness) is a recurrent mode disorder. The patient may feel stable at baseline level but experience recurrent shifts to an emotional high (mania or hypomania)
More informationPsychiatry: three favourite OSCE stations
Psychiatry: three favourite OSCE stations OSCE stations in psychiatry tend to fill medical students with dread. Psychiatric patients aren t as forthcoming when it comes to providing the interviewer with
More informationPrescribing Framework for Donepezil in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Donepezil in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP
More informationSummary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole)
EMA/303592/2015 Summary of the risk management plan (RMP) for Aripiprazole Pharmathen (aripiprazole) This is a summary of the risk management plan (RMP) for Aripiprazole Pharmathen, which details the measures
More informationOver the Counter Drugs (OTCs): Considerations for Physical Therapy Practice in Canada
Background Over the Counter Drugs (OTCs): Considerations for Physical Therapy Practice in Canada The use of medications or drugs by non-physician health professionals is evolving and is linked to collaboration
More informationGilenya. Exceptional healthcare, personally delivered
Gilenya Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Gilenya. The decision to start this form of treatment can be difficult.
More informationHumulin R (U500) insulin: Prescribing Guidance
Leeds Humulin R (U500) insulin: Prescribing Guidance Amber Drug Level 2 We have started your patient on Humulin R (U500) insulin for the treatment of diabetic patients with marked insulin resistance requiring
More informationDiabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
More informationDiagnosis: Appropriate diagnosis is made according to diagnostic criteria in the current Diagnostic and Statistical Manual of Mental Disorders.
Page 1 of 6 Approved: Mary Engrav, MD Date: 05/27/2015 Description: Eating disorders are illnesses having to do with disturbances in eating behaviors, especially the consuming of food in inappropriate
More informationMedication for the Treatment of Alcohol Use Disorder. Pocket Guide
Medication for the Treatment of Alcohol Use Disorder Pocket Guide Medications are underused in the treatment of alcohol use disorder. According to the National Survey on Drug Use and Health, of the estimated
More informationMedication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules
Medication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules Read this Medication Guide before you start taking EQUETRO and each time you get a refill. There may be new information. This
More informationPreconception Clinical Care for Women Medical Conditions
Preconception Clinical Care for Women All women of reproductive age are candidates for preconception care; however, preconception care must be tailored to meet the needs of the individual. Given that preconception
More informationTeriflunomide (Aubagio) 14mg once daily tablet
Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision
More informationClinical Aspects of Hyponatremia & Hypernatremia
Clinical Aspects of Hyponatremia & Hypernatremia Case Presentation: History 62 y/o male is admitted to the hospital with a 3 month history of excessive urination (polyuria) and excess water intake up to
More informationGUIDELINES FOR THE USE OF PALIPERIDONE PALMITATE (Xeplion ) Version: 2
SH CP 29 GUIDELINES FOR THE USE OF PALIPERIDONE PALMITATE (Xeplion ) Summary: Guidelines for the use of paliperidone palmitate (Xeplion ) Keywords (minimum of 5): (To assist policy search engine) Target
More information1. What are anti-epileptic drugs? Anti-epileptic drugs (AEDs) are prescribed to control seizures. They do not cure epilepsy.
14 FREQUENTLY ASKED QUESTIONS ON ANTI- EPILEPTIC DRUGS 1. What are anti-epileptic drugs? Anti-epileptic drugs (AEDs) are prescribed to control seizures. They do not cure epilepsy. 2. When should treatment
More informationLothian Diabetes Handbook MANAGEMENT OF DIABETIC KETOACIDOSIS
MANAGEMENT OF DIABETIC KETOACIDOSIS 90 MANAGEMENT OF DIABETIC KETOACIDOSIS Diagnosis elevated plasma and/or urinary ketones metabolic acidosis (raised H + /low serum bicarbonate) Remember that hyperglycaemia,
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
More informationIntroduction. Background to this event. Raising awareness 09/11/2015
Introduction Primary Care Medicines Governance HSCB Background to this event New class of medicines Availability of training Increasing volume of prescriptions Reports of medication incidents Raising awareness
More informationFAQs about Warfarin (brand name Coumadin )
FAQs about Warfarin (brand name Coumadin ) What is warfarin? Warfarin is the most commonly used anticoagulant in the US. An anticoagulant is a drug used to prevent unwanted and harmful blood clots. Although
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology. VI.2.2 Summary of treatment benefits
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pain is one of the most common reasons for a patient to seek medical attention. Moderate or severe intensity pain can be acute
More informationAmitriptyline. Drug information Amitriptyline
Drug information Amitriptyline Amitriptyline This leaflet provides information on amitriptyline and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets
More informationMEDGUIDE SECTION. What is the most important information I should know about SEROQUEL? SEROQUEL may cause serious side effects, including:
MEDGUIDE SECTION Medication Guide SEROQUEL (SER-oh-kwell) (quetiapine fumarate) Tablets Read this Medication Guide before you start taking SEROQUEL and each time you get a refill. There may be new information.
More informationAcquired, Drug-Induced Long QT Syndrome
Acquired, Drug-Induced Long QT Syndrome A Guide for Patients and Health Care Providers Sudden Arrhythmia Death Syndromes (SADS) Foundation 508 E. South Temple, Suite 202 Salt Lake City, Utah 84102 800-STOP
More informationDrugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement
Drugs for Alcohol Dependence: Clinical Guidance and Three Way Agreement for County Durham In partnership with the GP, the client, and the County Durham Drug and Alcohol Service December 2015 Version 1.0
More informationNHS ONEL and NELFT Shared Care Guidelines. Management of medications for Alzheimer s disease. Patient Name : Date of Birth: NHS No:
NHS ONEL and NELFT Shared Care Guidelines Management of medications for Alzheimer s disease DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name
More informationMS Treatments Gilenya
1 MSology Essentials Series Gilenya (fingolimod) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Trudy Campbell Dalhousie MS Research Unit, Capital Health, Halifax,
More informationAll Wales Prescription Writing Standards
All Wales Prescription Writing Standards These standards should be read in conjunction with completing the All Wales Medication Chart e- learning package, available on the Learning@NHSWales internet site
More informationMEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets
MEDICATION GUIDE Savella (Sa-vel-la) (milnacipran HCl) Tablets Savella is not used to treat depression, but it acts like medicines that are used to treat depression (antidepressants) and other psychiatric
More informationNICE Clinical guideline 23
NICE Clinical guideline 23 Depression Management of depression in primary and secondary care Consultation on amendments to recommendations concerning venlafaxine On 31 May 2006 the MHRA issued revised
More informationSt Bernard s Catholic School. Administration of Medicine Policy
St Bernard s Catholic School Page 1 of 10 The St Bernard s administration of medicine policy has been developed to ensure that children with medical needs have the same access to education as their peers
More informationIdentifying and treating long-term kidney problems (chronic kidney disease)
Understanding NICE guidance Information for people who use NHS services Identifying and treating long-term kidney problems (chronic kidney disease) NICE clinical guidelines advise the NHS on caring for
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection. Adrenaline (Levorenine, Epinephrine)
PACKAGE LEAFLET: INFORMATION FOR THE USER ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection Adrenaline (Levorenine, Epinephrine) Read all of this leaflet carefully before you start using this
More informationShare the important information in this Medication Guide with members of your household.
MEDICATION GUIDE BUPRENORPHINE (BUE-pre-NOR-feen) Sublingual Tablets, CIII IMPORTANT: Keep buprenorphine sublingual tablets in a secure place away from children. Accidental use by a child is a medical
More informationShared Care Agreement Insulin Degludec (Tresiba )
Licensed Indication Shared Care Agreement Insulin Degludec (Tresiba ) Insulin Degludec is licensed for the treatment of diabetes mellitus in adults. Countess of Chester prescribing guidelines Restricting
More informationTemozolomide (oral) with concurrent radiotherapy to the brain
Temozolomide (oral) with concurrent radiotherapy to the brain Temozolomide (oral) with concurrent radiotherapy to the brain This leaflet is offered as a guide to you and your family. You will find it useful
More information2. What Should Advocates Know About Diabetes? O
2. What Should Advocates Know About Diabetes? O ften a school district s failure to properly address the needs of a student with diabetes is due not to bad faith, but to ignorance or a lack of accurate
More informationSCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE
SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE 1 P a g e The following Operational Guidance Manual has been prepared with input from both community and prison addictions specialists
More informationTHE BASICS. Community Based Medically Assisted Alcohol Withdrawal. World Health Organisation 2011. The Issues 5/18/2011. RCGP Conference May 2011
RCGP Conference May 2011 Community Based Medically Assisted Alcohol Withdrawal THE BASICS An option for consideration World Health Organisation 2011 Alcohol is the world s third largest risk factor for
More informationConjoint Professor Brian Draper
Chronic Serious Mental Illness and Dementia Optimising Quality Care Psychiatry Conjoint Professor Brian Draper Academic Dept. for Old Age Psychiatry, Prince of Wales Hospital, Randwick Cognitive Course
More informationDiabetic Ketoacidosis
Princess Margaret Hospital for Children PAEDIATRIC ACUTE CARE GUIDELINE Diabetic Ketoacidosis Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should
More informationGalantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease
IS 17 October 2011 Information sheet Galantamine hydrobromide (Reminyl) Drug treatment for Alzheimer s disease Introduction... 1 How does Reminyl work?... 1 Who might benefit?... 2 What effect might Reminyl
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More information2.6.4 Medication for withdrawal syndrome
.6.3 Self-medication Self-medication presents a risk during alcohol withdrawal, particularly when there is minimal supervision (low level and medium level 1 settings). Inform patients of the risk of selfmedication
More informationTreatments for Major Depression. Drug Treatments The two (2) classes of drugs that are typical antidepressants are:
Treatments for Major Depression Drug Treatments The two (2) classes of drugs that are typical antidepressants are: 1. 2. These 2 classes of drugs increase the amount of monoamine neurotransmitters through
More informationMETHOTREXATE Rheumatoid arthritis, Psoriasis, Crohn s Disease & Ulcerative Colitis DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AND FILED IN NOTES
NHS ONEL and BHRuT NHS Trust Shared Care Guidelines METHOTREXATE Rheumatoid arthritis, Psoriasis, Crohn s Disease & Ulcerative Colitis DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AND FILED IN NOTES
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More informationACID- BASE and ELECTROLYTE BALANCE. MGHS School of EMT-Paramedic Program 2011
ACID- BASE and ELECTROLYTE BALANCE MGHS School of EMT-Paramedic Program 2011 ACID- BASE BALANCE Ions balance themselves like a see-saw. Solutions turn into acids when concentration of hydrogen ions rises
More informationGuidelines for the use of unlicensed and off label medication within NHS Fife Addiction Services
NHS Fife Community Health Partnerships Addiction Services Guidelines for the use of unlicensed and off label medication within NHS Fife Addiction Services Intranet Procedure No. A11 Author Dr A. Baldacchino
More informationLithium and long-term prophylactic treatment
Lithium and long-term prophylactic treatment 5 LITHIUM 5.1 What is lithium? 102 5.2 How was lithium discovered? 102 5.3 How does lithium work? 102 5.4 How effective is lithium? 102 5.5 What are the indications
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user LOSARTAN POTASSIUM 25 mg FILM-COATED TABLETS LOSARTAN POTASSIUM 50 mg FILM-COATED TABLETS LOSARTAN POTASSIUM 100 mg FILM-COATED TABLETS Losartan Potassium Read
More informationWhat Codeine Phosphate Tablets are used for
New Zealand Consumer Medicine Information CODEINE PHOSPHATE 15mg, 30mg & 60mg Tablets What is in this leaflet Please read this leaflet carefully before you start using Codeine Phosphate Tablets. This leaflet
More informationKeeping patients safe when they transfer between care providers getting the medicines right
PART 1 Keeping patients safe when they transfer between care providers getting the medicines right Good practice guidance for healthcare professions July 2011 Endorsed by: Foreword Taking a medicine is
More informationNonsteroidal. Drugs (NSAIDs) Anti-Inflammatory. North American Spine Society Public Education Series
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) North American Spine Society Public Education Series Nonsteroidal Anti- Inflammatory Drugs Your healthcare provider has recommended that you take a nonsteroidal
More informationClinical Audit: Prescribing antipsychotic medication for people with dementia
Clinical Audit: Prescribing antipsychotic medication for people with dementia Trust, team and patient information Q1. Patient's DIS number... Q2. Patient s residence: Home Residential Home Nursing Home
More informationReview of Pharmacological Pain Management
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
More informationBipolar disorder. Understanding NICE guidance
Understanding NICE guidance Information for people who use NHS services Bipolar disorder NICE clinical guidelines advise the NHS on caring for people with specific conditions or diseases and the treatments
More informationLiskonum 450 mg tablets lithium carbonate
GSK Logo Package Leaflet: Information for the User Liskonum 450 mg tablets lithium carbonate Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationThe management of bipolar disorder in adults, children and adolescents, in primary and secondary care
Quick reference guide Issue date: July 2006 Bipolar disorder The management of bipolar disorder in adults, children and adolescents, in primary and secondary care Developed by the National Collaborating
More informationBreast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail
Breast Pathway Group FEC 60 (Fluorouracil / Epirubicin / Cyclophosphamide) in Early Breast Cancer in Elderly / Frail Indication: Neoadjuvant or adjuvant therapy for elderly and frail patients with breast
More informationSHARED CARE GUIDELINE FOR TREATMENT OF DEMENTIA 1. Aim/Purpose of this Guideline
SHARED CARE GUIDELINE FOR TREATMENT OF DEMENTIA 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration
More informationGuidelines for Titration onto Buprenorphine in Opioid Dependence
NHS Fife Community Health Partnership Addiction Services Guidelines for Titration onto Buprenorphine in Opioid Dependence Intranet Procedure No. A7 Author Dr L. Cockayne Copy No 1 Reviewer Lead Clinician
More information